Lab
Laboratory Corporation of America
Laboratory Corporation of America was paid $3.03M by Medicaid between Jul 2023 and Dec 2024, across 177 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 6.3% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA
TROY, MI 48083
TROY, MI 48083
33aNPI1598491300assigned 07/26/2022
33bProvider typeClinical Medical Laboratory
28Total paid$3.03M
24GClaims340,324
24DCodes billed177
24AFirst – last monthJul 2023 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#21 of 108
Median peer was paid$588K
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 152,632 | $1.29M | |
| 2024incomplete | 187,692 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 6.3% | 24,732 | 24,320 | $193K |
| 84443 | Thyroid stimulating hormone (TSH) | 6.1% | 18,424 | 18,311 | $184K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.8% | 16,510 | 16,427 | $176K |
| 80061 | Lipid panel | 5.8% | 21,971 | 21,878 | $176K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.1% | 6,410 | 6,367 | $154K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.0% | 6,397 | 6,354 | $151K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.9% | 26,325 | 25,828 | $150K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.2% | 7,774 | 7,749 | $129K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 4.0% | 6,282 | 6,271 | $121K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 4.0% | 4,661 | 4,652 | $120K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.9% | 17,389 | 17,339 | $88K |
| 82607 | 2.7% | 8,702 | 8,679 | $80K |
165 more codes
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.6% | 5,129 | $79K |
| 84439 | 1.8% | 10,720 | $55K | |
| 86780 | 1.7% | 5,736 | $51K | |
| 86803 | 1.6% | 4,929 | $48K | |
| 84403 | 1.4% | 1,930 | $43K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 822 | $36K |
| 84153 | 1.2% | 2,881 | $36K | |
| 82728 | 1.1% | 4,487 | $35K | |
| 80074 | 1.1% | 1,661 | $34K | |
| 87340 | 1.0% | 4,476 | $31K | |
| 83970 | <1% | 934 | $29K | |
| 83550 | <1% | 5,402 | $28K | |
| 84702 | <1% | 3,482 | $27K | |
| 82670 | <1% | 1,252 | $26K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,159 | $24K |
| 85027 | <1% | 4,972 | $23K | |
| 83001 | <1% | 1,677 | $23K | |
| 84402 | <1% | 1,218 | $22K | |
| 84146 | <1% | 1,574 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,045 | $22K |
| 83540 | <1% | 5,674 | $22K | |
| 82746 | <1% | 1,944 | $21K | |
| 82570 | <1% | 5,236 | $20K | |
| 87481 | <1% | 324 | $20K | |
| 82043 | <1% | 4,622 | $20K | |
| 83735 | <1% | 3,741 | $19K | |
| 83002 | <1% | 1,289 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,732 | $18K |
| 84144 | <1% | 1,034 | $16K | |
| 81003 | <1% | 9,077 | $15K | |
| 84480 | <1% | 1,309 | $14K | |
| 84550 | <1% | 4,377 | $14K | |
| 86480 | <1% | 302 | $14K | |
| 86762 | <1% | 1,400 | $13K | |
| 82627 | <1% | 759 | $13K | |
| 86850 | <1% | 1,755 | $12K | |
| 86038 | <1% | 1,378 | $11K | |
| 84481 | <1% | 879 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 556 | $10K |
| 86696 | <1% | 741 | $9K | |
| 83880 | <1% | 339 | $8K | |
| 86140 | <1% | 2,134 | $8K | |
| 83690 | <1% | 1,665 | $8K | |
| 83013 | <1% | 173 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 196 | $8K |
| 82550 | <1% | 1,701 | $7K | |
| 87563 | <1% | 297 | $7K | |
| 82105 | <1% | 563 | $6K | |
| 86235 | <1% | 169 | $6K | |
| 84460 | <1% | 1,513 | $6K | |
| 84100 | <1% | 1,542 | $5K | |
| 84450 | <1% | 1,452 | $5K | |
| 86695 | <1% | 610 | $5K | |
| 86364 | <1% | 414 | $5K | |
| 82950 | <1% | 1,439 | $5K | |
| 87536 | <1% | 84 | $5K | |
| 85652 | <1% | 2,445 | $5K | |
| 82150 | <1% | 1,098 | $5K | |
| 86376 | <1% | 450 | $5K | |
| 84154 | <1% | 354 | $4K | |
| 82747 | <1% | 396 | $4K | |
| 86800 | <1% | 386 | $4K | |
| 84134 | <1% | 401 | $4K | |
| 86705 | <1% | 514 | $4K | |
| 86258 | <1% | 284 | $4K | |
| 84425 | <1% | 265 | $4K | |
| 83525 | <1% | 481 | $4K | |
| 82565 | <1% | 1,109 | $4K | |
| 86709 | <1% | 501 | $4K | |
| 83498 | <1% | 205 | $4K | |
| 83615 | <1% | 985 | $4K | |
| 82166 | <1% | 195 | $4K | |
| 86431 | <1% | 882 | $4K | |
| 86200 | <1% | 407 | $3K | |
| 82784 | <1% | 290 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 60 | $3K |
| 83655 | <1% | 364 | $3K | |
| 80076 | <1% | 540 | $3K | |
| 86787 | <1% | 442 | $3K | |
| 83020 | <1% | 405 | $3K | |
| 80197 | <1% | 319 | $3K | |
| 81001 | <1% | 1,365 | $3K | |
| 87070 | <1% | 608 | $3K | |
| 82040 | <1% | 880 | $3K | |
| 86901 | <1% | 1,577 | $3K | |
| 86900 | <1% | 1,578 | $3K | |
| 85610 | <1% | 1,198 | $3K | |
| 88142 | <1% | 187 | $3K | |
| 84630 | <1% | 349 | $3K | |
| 86706 | <1% | 383 | $3K | |
| 82947 | <1% | 1,019 | $3K | |
| 83721 | <1% | 411 | $3K | |
| 84520 | <1% | 962 | $3K | |
| 82525 | <1% | 300 | $3K | |
| 82248 | <1% | 742 | $3K | |
| 83921 | <1% | 199 | $3K | |
| 82533 | <1% | 225 | $3K | |
| 82652 | <1% | 198 | $3K | |
| 86225 | <1% | 281 | $3K | |
| 82247 | <1% | 724 | $3K | |
| 84156 | <1% | 927 | $2K | |
| 84075 | <1% | 686 | $2K | |
| 86592 | <1% | 752 | $2K | |
| 86704 | <1% | 292 | $2K | |
| 86003 | <1% | 35 | $2K | |
| 86141 | <1% | 212 | $2K | |
| 86231 | <1% | 283 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 62 | $2K |
| 82310 | <1% | 539 | $2K | |
| 80069 | <1% | 290 | $2K | |
| 84703 | <1% | 420 | $2K | |
| 85730 | <1% | 606 | $2K | |
| 88141 | <1% | 104 | $2K | |
| 84466 | <1% | 215 | $2K | |
| 82977 | <1% | 340 | $2K | |
| 80051 | <1% | 301 | $1K | |
| 84155 | <1% | 522 | $1K | |
| 82951 | <1% | 129 | $1K | |
| 87088 | <1% | 235 | $1K | |
| 87186 | <1% | 193 | $1K | |
| 87077 | <1% | 200 | $1K | |
| 86317 | <1% | 98 | $1K | |
| 86708 | <1% | 123 | $1K | |
| 86160 | <1% | 55 | $939.04 | |
| 80081 | <1% | 16 | $888.21 | |
| 82274 | <1% | 70 | $885.21 | |
| 84295 | <1% | 255 | $842.73 | |
| 82465 | <1% | 301 | $842.18 | |
| 87081 | <1% | 204 | $841.75 | |
| 82435 | <1% | 261 | $841.06 | |
| 85660 | <1% | 246 | $832.25 | |
| 82374 | <1% | 218 | $712.86 | |
| 87625 | <1% | 17 | $668.76 | |
| 80164 | <1% | 66 | $626.71 | |
| 86304 | <1% | 57 | $543.89 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12 | $534.84 |
| 85018 | <1% | 278 | $473.51 | |
| 85014 | <1% | 264 | $450.52 | |
| 86765 | <1% | 59 | $437.44 | |
| 82397 | <1% | 149 | $431.64 | |
| 85045 | <1% | 139 | $412.94 | |
| 84165 | <1% | 63 | $364.43 | |
| 84436 | <1% | 79 | $349.38 | |
| 84207 | <1% | 17 | $341.10 | |
| 87641 | <1% | 12 | $340.20 | |
| 86301 | <1% | 28 | $313.08 | |
| 82378 | <1% | 44 | $311.28 | |
| 82952 | <1% | 97 | $300.65 | |
| 87799 | <1% | 13 | $278.56 | |
| 86361 | <1% | 12 | $265.07 | |
| 87529 | <1% | 12 | $260.80 | |
| 87535 | <1% | 13 | $248.05 | |
| 84681 | <1% | 16 | $244.52 | |
| 86665 | <1% | 16 | $212.67 | |
| 86037 | <1% | 14 | $196.43 | |
| 84132 | <1% | 53 | $186.99 | |
| 82785 | <1% | 18 | $185.15 | |
| 86778 | <1% | 25 | $175.70 | |
| 86777 | <1% | 25 | $175.38 | |
| 84202 | <1% | 15 | $164.78 | |
| 88164 | <1% | 13 | $129.47 | |
| 81025 | <1% | 15 | $66.18 | |
| 86593 | <1% | 20 | $48.18 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 14 | $0.00 |
| 80050 | General health panel | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.